
Epigenetic Signatures of In Vitro and In Vivo Experimental Models Employed in Non-small Cell Lung Cancer and the Unique miR-148b-3p/PVT1/ZBTB7A Regulatory Network Discriminating Large Cell Lung Carcinoma

Magda Spella , [Eleftherios Bochalos](#) , Katerina Athanasopoulou , Argyri Chroni , [Irene Dereki](#) , [Giannoula Ntaliarda](#) , Ifigeneia Makariti , [Georgios Psarias](#) , Caterina Constantinou , [Vasiliki Chondrou](#) , [Argyro Sgourou](#) *

Posted Date: 30 October 2023

doi: 10.20944/preprints202310.1943.v1

Keywords: Non-small cell lung cancer; epigenetic deregulation; micro-RNAs; long non-coding RNAs; epigenetically motivated transcription factors; epigenetic networks



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Epigenetic Signatures of In Vitro and In Vivo Experimental Models Employed in Non-Small Cell Lung Cancer and the Unique miR-148b-3p/PVT1/ZBTB7A Regulatory Network Discriminating Large Cell Lung Carcinoma

Magda Spella ^{1,2}, Eleftherios Bochalos ¹, Katerina Athanasopoulou ¹, Argyri Chroni ¹, Irene Dereki ¹, Giannoula Ntaliarda ², Ifigeneia Makariti ¹, Georgios Psarias ¹, Caterina Constantinou ¹, Vasiliki Chondrou ¹ and Argyro Sgourou ^{1,*}

¹ Biology Laboratory, School of Science and Technology, Hellenic Open University, 26335 Patras, Greece

² Department of Physiology, Faculty of Medicine, University of Patras, Rio, 26504, Greece

* Correspondence: sgourou@eap.gr

Abstract: Epigenetic approaches in direct correlation with assessment of critical genetic mutations in non-small cell lung cancer (NSCLC) are currently very intensive, as the epigenetic components in NSCLC development and progression have attained high recognition. In this level of research, established human NSCLC cell lines as well as experimental animals are widely used to detect novel biomarkers and pharmacological targets to treat NSCLC. The epigenetic background of NSCLC is highly complex and requires precise definition as these phenomena are variable between NSCLC subtypes and systems origin. We engaged an in-depth characterization of non-coding (nc)RNAs prevalent in human *KRAS*-mutant NSCLC cell lines A549 and H460 and mouse *KRAS*-mutant NSCLC tissue by Next Generation Sequencing (NGS) and quantitative Real Time PCRs (qPCRs). Also, the effect of transcription factor (TF) LRF, a known epigenetic silencer, was examined on the epigenome modulation. Finally, interacting networks underlying epigenetic variations in NSCLC subtypes were created. Data derived from our study highlights the divergent epigenetic profiles of NSCLC of human and mouse origin, as well as the significant contribution of 12qf1: 109,709,060-109,747,960 mouse chromosomal region to micro-RNA upregulated species. Furthermore, the novel epigenetic miR-148b-3p/PVT1/ZBTB7A axis was identified, which differentiates lung adenocarcinoma from large cell lung carcinoma, two characteristic NSCLC subtypes. The detailed recording of epigenetic events in NSCLC and combinational studies including networking between ncRNAs and TFs validate the identification of significant epigenetic features, prevailing in NSCLC subtypes and among experimental models. Our results enrich knowledge in the field and empower research on the epigenetic prognostic biomarkers of the disease and patient-tailored treatments.

Keywords: non-small cell lung cancer; epigenetic deregulation; micro-RNAs; long non-coding RNAs; epigenetically motivated transcription factors; epigenetic networks

1. Introduction

Non-small cell lung cancer (NSCLC) is a leading cause for high morbidity and mortality rates worldwide. NSCLC can be further divided into three major histological subtypes: lung adenocarcinoma (LUAD), large cell carcinoma, and squamous cell carcinoma with distinct phenotypes (1). On the genetic level, coexistence of activating mutations of the Kirsten rat sarcoma viral oncogene homologue (*KRAS*) is a common NSCLC hallmark (2). The molecular signatures of candidate genes, epigenetically regulated by differential DNA methylation profiles have also been implicated in NSCLC as complements to already known driver mutations. Among reported epigenetically modified DNA gene loci, genes encoding non-coding RNAs (ncRNAs) are also included and represent features of high importance for the NSCLC progression and response to drugs [3], as available therapies are challenging and upon administration offer extended life just by a few months. Platinum-containing drugs such as cisplatin and carboplatin are typically used as the

first-line chemotherapeutic agents for the treatment of NSCLC, sometimes in combination with surgical excision and chest radiotherapy [4]. Nevertheless, advanced stages of the disease often evolve resistance to chemotherapeutics and within this frame strong research efforts and innovative approaches are necessary to improve patients' quality of life and survival, since the efficacies of current therapies are limited. So far, extensive research associated with the NSCLC therapeutics has employed human samples, established human malignant cell lines and mainly mice as experimental system models. However, investigation in living cells (cell lines and mouse models) that display unique genetic/epigenetic characteristics should be cautiously interpreted for the specificity of imprinted results and efficacy of recommended treatments for humans.

Apart from driver mutations characterized as a leading cause of NSCLC, subtle combinations of epigenetic events with hereditary potential are also associated with NSCLC progression and chemotherapeutic resistance development. Aberrant epigenetic signatures have a realistic prospect and can serve as a pragmatic approach towards the identification of functional epigenetic events and potential circuits guiding cancer development and progression. Epigenetic marks include histone code and DNA modifications simultaneously with non-coding RNA (ncRNA) tissue-specific production, accounting for the active epigenome of human tissues and playing fundamental roles in cancer [5]. These biochemical events, contrary to the established genetic mutations, sometimes represent only a snapshot of cellular life during the cell cycle and can be reversible, justifying their importance as promising therapeutic targets.

Epigenetically altered chromatin supports positively or negatively ncRNAs' transcription depending on the conditions prevailing across genetic loci coding for the various ncRNA species. Aberrant micro-RNA (miRNA) expression has been extensively studied and miRNAs are proposed as lung cancer subtype classifiers [6], prognostic and drug-response biomarkers [7,8] and as targets for novel miRNA-based treatment approaches [9]. Clinical implementation strategies and potential of lncRNAs in NSCLC have also been extensively reported [10]. MiRNA clusters and lncRNAs are considered mainly as products of RNA polymerase II and therefore, the transcription of these primary transcripts is regulated by general TFs and signal transduction pathways. Deregulation of TFs' expression and consequent tissue-imbalanced lncRNA expression is often sufficient for the development of several human disorders and for malignant cell transformation [11]. In addition to sharing certain characteristics with "ordinary" genes, such as splicing, polyadenylation etc., many genetic loci transcribing miRNAs and lncRNAs include CpG islands with conditional regulatory role on their expression. Also, genetic loci of lncRNAs encompass miRNA genes with contingent coregulation of both species by the same elements. A well-known epigenetically motivated TF, the lymphoma/Leukemia related factor (LRF) belongs to an evolutionarily conserved family of TFs with zinc finger domains, which have been assigned with regulatory properties concerning gene expression and binding preference at CG-rich and CpG island containing promoters. LRF derives from *ZBTB7A* gene and recently we investigated its capability of regulating lncRNAs [12] on the transcriptional level during erythropoiesis while, it has been also involved in various cancer types development [13]. Herein, all above mentioned epigenetic components constitute a network underlying critical alterations that deceitfully function in NSCLC.

Lung cancer research in living cells relies largely on experimental models consisting of human and mouse established malignant cell lines with specific characteristics and animal experimental models, mainly mice. In this study, we have analyzed and compared epigenetic features exhibited by different NSCLC experimental models, to determine and characterize significant epigenetic signatures. We have comprehensively studied miRNA profiles in two *KRAS*-mutant NSCLC human cell lines (A549 and H460) and in *Kras*-mutant NSCLC mouse lung malignant and adjacent normal tissue. Additionally, we have assessed methylation and expression profiles of human lncRNAs with known altered patterns in NSCLC. Our results strongly point out different mechanisms of carcinogenesis evolution between mouse NSCLC tissue and human NSCLC cell lines (A549 and H460), simultaneously with considerable epigenetic diversity among the human cell lines, reflecting distinct malignant histological subtype-dependent behaviors. Also, our results support the existence of a miRNA/lncRNA/*ZBTB7A* epigenetic network in human large-cell lung carcinoma H460 cell line,

leading to the suppression of *LRF/ZBTB7A* expression. The present study provides comprehensive and elaborate information on the epigenetic features prevailing in each tested experimental model defined as NSCLC. This kind of information is considered critical during selection of appropriate biological models for studies and drug discovery and offers new knowledge in the field of biomarkers investigation.

2. Materials and Methods

2.1. Cell culture

The A549 (*KRAS*^{G12S}) and H460 (*KRAS*^{Q61H}) NSCLC cell lines of human origin as well as HEK293 (human embryonic kidney cells) were cultured in a humidified atmosphere with 5% CO₂ at 37°C in Dulbecco's Modified Eagle Medium (DMEM, Sigma). The medium was supplemented with 10% fetal bovine serum (FBS, Gibco—Thermo Fisher Scientific Inc., Grand Island, NE, USA), 100 units/mL penicillin, and 100 µg/mL streptomycin (Sigma -Aldrich Pty Ltd, An affiliate of Merck KGaA, Darmstadt, Germany). The cells were passaged every two days. A549 and H460 cell lines have the *KRAS* mutations c.34G>A (ClinVar=VCV000012584) and c.183A>T (ClinVar=VCV000045117) respectively, of the most prevalent mutations verified in NSCLC [14].

Human bronchial epithelial cell line BEAS-2B was cultured in Bronchial Epithelial Cell Growth Medium (BEGM) consisting of Bronchial Epithelial Cell Basal Medium (BEBM, Lonza Group AG, Basel, Switzerland Catalog No.: CC-3171), supplemented with 0.4% Bovine Pituitary Extract (BPE), 0.1% Insulin, 0.1% Hydrocortisone, 0.1% GA-1000, 0.1% Retinoic Acid, 0.1% Transferrin, 0.1% Triiodothyronine, 0.1% Epinephrine, 0.1% human Epidermal Growth Factor (hEGF) (BEGM SingleQuots kit, Lonza Group AG, Basel, Switzerland, Catalog No.: CC-4175) and 100 units/mL penicillin and 100 µg/mL streptomycin (Sigma -Aldrich Pty Ltd, An affiliate of Merck KGaA, Darmstadt, Germany). Gentamicin/Amphotericin-B, present as GA-1000 in the BEGM SingleQuots kit, was added 3 days after culture starting date, to minimize excessive cell stress originating from cryopreservation. The cells were passaged every 2 days. Upon confluency, genomic DNA and total RNA were extracted for downstream analysis.

2.2. Mouse models of NSCLC

In our experimental design 6-week-old FVB/NJ (FVB; #001800) mice from Jackson Laboratories (Bar Harbor, MN) were introduced. Mice were bred at the Center for Animal Models of Disease of the University of Patras, maintained on a regular light-dark cycle (lights on from 8:00 a.m. to 8:00 p.m.) at an ambient temperature of 22 ± 1°C and allowed free access to standard rodent chow diet and water.

All mice received 1 g/Kg BW urethane via one intraperitoneal injection and were euthanized 6 months after urethane administration. Urethane is a chemical carcinogen contained in tobacco smoke and this regime is successful in triggering NSCLC (notably LUAD with *KRAS*^{Q61R} mutations) in mice, as previously described [15,16]. After euthanasia, tissues of interest (liver, spleen and lung, including both lung tumors and matching adjacent normal tissue) were collected, washed in cold PBS, snap frozen in liquid nitrogen and stored for subsequent analysis. For histological confirmation of malignancy, lung samples, both malignant and normal were inflated and fixed with 10% formalin overnight and were initially inspected macroscopically under a Stemi DV4 stereoscope equipped with an AxiocamERc 5s camera (Zeiss, Jena, Germany) in trans-illumination mode. Lung samples were then embedded in paraffin, and five-mm-thick paraffin sections were counterstained with hematoxylin and eosin (Sigma, St. Louis, MO) and mounted with Entellan New (Merck Millipore, Darmstadt, Germany). Bright-field images were captured with an AxioLab.A1 microscope connected to an AxioCamERc 5s camera (Zeiss, Jena, Germany).

All animal experiments were approved *a priori* by the Veterinary Administration of the Prefecture of Western Greece (approval numbers 3741/16.11.2010, 60291/3035/19.03.2012, and 118018/578/30.04.2014) and conducted according to Directive 2010/63/EU (<http://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1486710385917&uri=CELEX:32010L0063>).

2.3. Selection of human lncRNAs implicated in lung cancer

Human lncRNAs selected for the present study have been previously related to lung cancerous state in humans. The study was limited to human tissues because there is no evolutionary conservation between human and mice lncRNAs. Among selected lncRNAs, HOXA Antisense RNA (*HOTAIRM1*), Maternally Expressed 3 (*MEG3*), Differentiation Antagonizing Non-Protein Coding RNA (*DANCR*), Plasmacytoma Variant Translocation 1 (*PVT1*), Metastasis Associated Lung Adenocarcinoma Transcript 1 (*MALAT1*) and Imprinted Maternally Expressed Transcript *H19* [17–22] are annotated by several databases (ENA, LncBook, Ensembl, LNCipedia, Ensembl/GENCODE, GeneCards). Sequences and chromosomal locations of CpG islands, mainly at transcriptional start site (TSS) of lnc-RNA sequences, were tracked from UCSC Genome browser (<https://genome-euro.ucsc.edu/cgi-bin/hgGateway>) (**Table 1**).

Table 1. Human lncRNAs and CpG chromosomal locations analyzed.

lncRNA gene	CpG island	Region analyzed
<i>DANCR</i>	93	Chr4: 52712612-52712726
<i>H19</i>	36	Chr11:1996329-1996211
<i>HOTAIRM1</i> <i>upstream</i>	116	Chr7:27095663-27095791
<i>HOTAIRM1</i> <i>downstream</i>	116	Chr7: 27096410-27096495
<i>MALAT1</i>	50	Chr11:65497584-65497709
<i>MEG3</i>	45	Chr14:100826116-100826218
<i>MEG3</i>	78	Chr14:100827449-100827521
<i>PVT1</i>	94	Chr8:127794107-127794229

2.4. CpG methylation analysis of human origin lncRNAs assessed by Pyrosequencing

Pyrosequencing methylation assay was utilized to assess DNA methylation status across CpG islands located at 5' prime ends of lncRNAs' genetic loci. Genomic DNA was extracted from human A549, H460 and BEAS-2B cell lines with phenol:chloroform:isoamyl alcohol in a 25:24:1 ratio following standard protocol (Sigma-Aldrich Pty Ltd, An affiliate of Merck KGaA, Darmstadt, Germany) [23]. 1.5µg of isolated genomic DNA was bisulfite converted, PCR amplified and sequenced with PyroMark® technology (QIAGEN GmbH, Hilden, Germany), according to manufacturer's instructions and as previously described [24]. Briefly, the biotinylated strand of the PCR products was immobilized by streptavidin-coated sepharose beads (Streptavidin Sepharose™ High Performance, GE HealthCare), and subsequently annealed with a Pyrosequencing primer. Pyrosequencing process was performed using the PyroMark® Gold Q24 Reagents (QIAGEN GmbH, Hilden, Germany) and PyroMark Q24 instrument. Primer sets are listed in **Supplementary Table S1** and every reaction was performed in duplicate.

2.5. Expression profiles of human origin lncRNAs assessed by qPCRs

Total RNA was extracted from A549, H460, HEK293 and BEAS2B cultivated cells using the miRNeasy Mini kit (74104), Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. 1µg of total RNA was converted to cDNA by miScript II RT kit (218161, Qiagen GmbH, Hilden, Germany). LRF/*ZBTB7A* and lncRNAs expression levels were assessed by qPCRs with sequence specific primer sets (**Supplementary Table S1**), designed to support detection of the main

transcripts of each lncRNA genetic loci. Reactions performed in Rotor-Gene Q instrument (QIAGEN GmbH, Hilden, Germany) using the PowerTrack SYBRGreen Master Mix (A46012, Thermo Fisher Scientific, Waltham, MA, USA). Each reaction was performed in triplicate. The $2^{-\Delta\Delta CT}$ method or Pfaffl equation with PCR efficiency correction was used for data analysis [25,26]. Fold changes in gene expression were normalized to the *GAPDH* reference gene and calculated relatively to either BEAS-2B or HEK293 cell line calibrator sample. Undetectable expression levels were assigned to lncRNAs with Cq values above acceptable limits (above 32-33 PCR cycles). SPSS software version 20.0 was used for data analysis. One way-Anova with Tukey's multiple comparisons post hoc tests or t-test were applied to compare expression levels between the different groups. P-values < 0.05 were considered statistically significant.

2.6. Human and mouse miRNA NSCLC profiles determined by Next Generation sequencing (NGS)

Total RNA including microRNA species was purified from A549, H460 and BEAS-2B human cultivated cells, as well as from three NSCLC lung tumors (LUAD) and matching adjacent normal tissues from FVB mice treated with urethane. Libraries were constructed from RNA samples using the QIAseq miRNA library kit (QIAGEN GmbH, Hilden, Germany). As an initial step, adapters were ligated to the 3' and 5' ends of miRNAs and subsequently, universal cDNA synthesis with Unique Molecular Indices (UMI) assignment, cDNA cleanup, library amplification and library cleanup were performed. Downstream RNA sequencing reactions were performed in Illumina iSeq 100 instrument (Illumina, Inc., US) in single-ended mode with 75 bp sequence length and total reads ranging from 1.0 to 1.5 million per sample. FastQC version 0.11.9 [27] was used for quality assessment of the sequenced libraries, before downstream FASTQ file analysis. UMIs present in each sample were extracted using UMI-tools version: 1.1.2 [28] and are to be later used for deduplicating counts. The extraction pattern follows a regular expression pattern (RegEx) that searches each sequence for the 3' adapter and extracts the following 12 bases as UMI and discarding any nucleotides after that, using the parameters "extract-method=regex--bc-pattern='.(?P<discard_1>AACTGTAGGCACCATCAAT){s<=2}(?P<umi_1>.{12})(?P<discard_2>.)'". UMI-extracted sequencing reads with lengths lower than 18 nucleotides were discarded using Cutadapt version 4.2 (29). Subsequently, hairpin and mature miRNAs were mapped to their corresponding genomes using Bowtie2 version 2.5.1 [30]. Homo sapiens miRNA FASTA files were obtained from miRBase release 22.1 [31]. We performed three rounds of alignment, one for precursor miRNAs, also known as hairpin miRNA, one for mature miRNA and one for genome aligned mature miRNA. Firstly, the hairpin miRNA sequencing reads were aligned to the hairpin miRNA miRBase genome using the parameters "--local --very-sensitive --no-unal -N 0 -k 1 --threads 16". Reads were later processed to obtain mature miRNA counts using the same Bowtie2 parameters as before. Unaligned mature miRNA sequencing reads were re-aligned to the human reference genome (GRCh38) with Bowtie2 using the parameters "--local --very-sensitive --no-unal -N 1 -k 1 --threads 16", allowing now for single [1] mismatch rather than the strict no mismatch used in the original alignment round.

Original count files for the miRBase aligned sequencing reads were created with the use of Samtools version 1.16 [32] using the sort and index tools. For the GRCh38 aligned reads we used the htseq-count tool from the HTSeq version 2.0.2 package [33] with the parameters "-f bam -m union -s yes -r name -t miRNA -i product". Finally, both miRBase and GRCh38 aligned count files were deduplicated, in order to minimize falsely overestimated counts, with the use of UMI-tools dedup tool and the option "--method=unique". Mature miRNA miRBase counts were combined with the GRCh38 mature miRNA counts using custom in-house Python scripts.

The same pipeline was implemented for the analysis of the NSCLC mouse samples. The alignment of the miRNAs was performed on the GRCh38 mouse reference genome. Differentially expressed hairpin and mature miRNAs were identified with the R package DESeq2 [34], where counts lower than 1000 were discarded and a log fold-change cutoff of ± 1 and an adjusted p-value cutoff of 0.05 were applied. Total miR reads displayed by NGS analysis are listed in **Supplementary Tables S2 A-D** (human) and **S3** (mouse).

2.7. Analysis workflow

To investigate the epigenetic landscape of human and mouse NSCLC, we have initially assessed the differential expression patterns of *ZBTB7A* human and *zbtb7a* mouse genes in *KRAS*-mutant NSCLC, compared to the human bronchial epithelial cell line BEAS-2B (normal) and to normal mouse lung tissue respectively. Subsequently, we performed methylation screening in CpG islands flanking lncRNAs and correlated methylation with expression levels of 6 selected lncRNAs that are confirmed for their implication in human lung cancer. lncRNAs are not conserved between humans and mice contrary to miRNA families, which are highly conserved among mammals and other organisms and thus, mouse samples were subjected only to miRNA qualitative and quantitative analysis. Both mouse and human samples were subjected to NGS analysis to determine miRNAs differentiated in NSCLC and normal tissue and a network of potential interrelationships was built. An experimental outline, as well as processing workflow are given in **Figure 1**.




Figure 1. Flow diagram of experimental processes performed with different experimental models of the study.

2. Results

3.1. Differential expression profiles of *LRF/ZBTB7A* and methylation/expression profiles of lncRNAs

Comparisons of mouse *lrf/zbtb7a* expression levels between lung and other tissues (liver and spleen) showed a significant upregulation of *lrf/zbtb7a* expression in mouse lung. Similarly, *LRF/ZBTB7A* was significantly overexpressed in human BEAS-2B cells compared to HEK293 immortalized human embryonic kidney cells. When we questioned *lrf/zbtb7a* expression in NSCLC samples of FVB mice treated with urethane compared to adjacent normal lung tissue, we found similar expression levels between malignant and normal lung tissue (**Figure 2A,C**); this was further corroborated in human samples, as BEAS-2B and A549 LUAD cells expressed same levels of *LRF/ZBTB7A* (**Figure 2B,D**). Interestingly however, H460 large cell carcinoma cell line exhibited significantly reduced levels of *LRF/ZBTB7A* expression compared to both BEAS-2B and A549 cells, possibly indicating a differential pathway of *LRF/ZBTB7A* expression in this subtype of NSCLC.

Methylation and expression assays were performed in six [6] selected human lncRNAs (**Table 1**) to reveal correlations between methylation and expression levels (heatmaps of **Figure 2E**). CpGs 93 and 50 of *DANCR*- and *MALAT1*-lncRNAs respectively, were unmethylated representing full

accessibility for the transcriptional machinery although, A549 cells displayed 70% reduced levels of expression for DANCR-lncRNA. MALAT1-lncRNA was not detected in any of the cell lines tested with qPCR, as well as HOTAIRM1-lncRNA. Among the rest of lncRNAs analyzed, decreased expression levels of each lncRNA were analogous to the elevation of methylation status across CpG island. CpGs 36, 116, 45, 78 and 94 of H19-, HOTAIRM1, MEG3-, MEG-3 and PVT1-lncRNAs respectively, were mainly hypermethylated in H460 cell line (**Figure 2E**). Methylation status of MEG3 CpG 45 directly upstream CpG 78, exhibited half values of methylation (45%) in BEAS-2B and A549 cells compared to CpG 78, which can be attributed to the CTCF insulator protein binding site, residing between these two rich CpG sequences [UCSC genome browser (<https://genome-euro.ucsc.edu/cgi-bin/hgGateway>)] and obstructing hypermethylation spreading. LncRNA methylation and expression levels are further discussed in the last paragraph of “results” section in direct correlation with results from miRNA expression and within the frame of potential interconnection of their functions.




Figure 2. (A) Representative stereoscopic images of whole lungs (left panel) and microscopic images of hematoxylin/eosin-stained sections (right panel) of lung adenocarcinomas (LUAD) induced in FVB mice by 1 intraperitoneal injection of 1 g/Kg urethane (six months latency). Dashed circles outline

tumors. (B) Human cell lines subjected to analysis (C) *lrf/zbtb7a* was significantly overexpressed in normal mouse lung tissue compared to other physiological tissues (liver and spleen) and comparable between mouse NSCLC and adjacent normal lung tissue. *** $p < 0.001$ (D) *LRF/ZBTB7A* levels were significantly lower in human HEK293 compared to BEAS-2B cells. Human BEAS-2B and A549 LUAD cells exhibited equal *LRF/ZBTB7A* expression levels, in contrast to H460 large cell carcinoma human cell line which presented significantly lower expression of *LRF/ZBTB7A*. ** $p < 0.01$ (E) Methylation profiles of CpG islands flanking TSS of lncRNAs in A549, H460 and BEAS-2B human cell lines. Each box corresponds to a Cytosine followed by Guanosine across the CpG island sequence. Data are presented as mean percentage methylation.

3.2. Sets of mouse miRs differentially expressed between NSCLC and normal lung tissue

To identify miRs of mouse origin (mmu-miRs) that are differentially expressed in NSCLC, RNA samples from six different NSCLC tumors (experimentally developed according to [16]) and four RNA samples from adjacent normal mouse lung tissues, were utilized for miR library development, next generation sequencing and subsequent bioinformatics analysis.

Table 2 lists distinguished miRs either overexpressed or underexpressed in mouse NSCLC tissue. Both hairpin and mature forms of miRs were determined. Reads with counts lower than 1000 were discarded. Differentially expressed miRNAs were considered those with an adjusted p-value < 0.05 and a log2fold change cutoff of ± 1 . Also, mmu-miR families indicating other miR members with seed sequence of close similarity implying same gene targeting and chromosomal locations of mmu-miR clusters (when applicable) indicating chromosomal locations with altered transcriptional regulation upon malignant development, are also listed in the table.

Table 2. Hairpin and mature deregulated mouse miRs found by NGS analysis with the respective family and cluster, according to miRBase. Chromosomal locations refer to miR clusters.

	Gene				
	miR hairpin	Mature miR	famil y	miR cluster	Chromosomal location
UPREGULATED	mmu-mir-200b	mmu-mir-200b-3p	mir-8	mmu-mir-200b	chr4: 156055681-156055750 [-]
	mmu-mir-200a	mmu-mir-200a-3p		mmu-mir-200a	chr4: 156054896-156054985 [-]
	mmu-mir-429	mmu-mir-429-3p		mmu-mir-429	chr4: 156053905-156053987 [-]
	mmu-mir-200c	mmu-mir-200c-3p	mmu-mir-200c	mmu-mir-141	chr6: 124718322-124718390 [-] chr6: 124717914-124717985 [-]
	mmu-mir-141	mmu-mir-141-5p mmu-mir-141-3p			
	mmu-mir-379	mmu-mir-379-5p	mir-379	*mmu-mir-379	chr12: 109709060-109709125 [+]

mmu-mir-411	mmu-mir-411-5p		mmu-mir-411	chr12: 109710175-109710256 [+]
mmu-mir-299a	mmu-mir-299a-5p	mir-299	mmu-mir-299a	chr12: 109710638-109710700 [+]
	mmu-mir-299a-3p		mmu-mir-299b	chr12: 109710645-109710693 [-]
mmu-mir-376c	mmu-mir-376c-3p	mir-367	mmu-mir-380	chr12: 109711803-109711863 [+]
mmu-mir-376b	mmu-mir-376b-5p		mmu-mir-1197	chr12: 109712317-109712436 [+]
	mmu-mir-376b-3p		mmu-mir-323	chr12: 109712508-109712593 [+]
mmu-mir-376a	mmu-mir-376a-3p		mmu-mir-758	chr12: 109712810-109712890 [+]
mmu-mir-134	mmu-mir-134-5p	mir-134	mmu-mir-329	chr12: 109713481-109713577 [+]
mmu-mir-300	mmu-mir-300-3p	mir-154	mmu-mir-494	chr12: 109715318-109715402 [+]
mmu-mir-381	mmu-mir-381-3p		mmu-mir-679	chr12: 109715577-109715650 [+]
mmu-mir-382	mmu-mir-382-5p		mmu-mir-1193	chr12: 109715671-109715791 [+]
mmu-mir-154	mmu-mir-154-5p		mmu-mir-666	chr12: 109717085-109717183 [+]
mmu-mir-377	mmu-mir-377-3p		mmu-mir-543	chr12: 109717258-109717333 [+]
mmu-mir-369	mmu-mir-369-5p		mmu-mir-495	chr12: 109718754-109718816 [+]
	mmu-mir-369-3p		mmu-mir-667	chr12: 109720006-109720097 [+]
mmu-mir-409	mmu-mir-409-5p		mmu-mir-376c	chr12: 109722718-109722803 [+]

		mmu-mir-409-3p		mmu-mir-654	chr12: 109723218-109723301 [+]
	mmu-mir-494	mmu-mir-494-3p		mmu-mir-376b	chr12: 109723458-109723539 [+]
	mmu-mir-541	mmu-mir-541-5p	mir-541	mmu-mir-376a	chr12: 109723781-109723848 [+]
	mmu-mir-329	mmu-mir-329-5p	mir-329	mmu-mir-300	chr12: 109724313-109724391 [+]
				mmu-mir-381	chr12: 109726822-109726896 [+]
				mmu-mir-487b	chr12: 109727333-109727414 [+]
				mmu-mir-539	chr12: 109728129-109728202 [+]
				mmu-mir-544	chr12: 109729325-109729402 [+]
				mmu-mir-382	chr12: 109733771-109733846 [+]
				mmu-mir-134	chr12: 109734139-109734209 [+]
	mmu-mir-1193	mmu-mir-1193-3p	mir-1193	mmu-mir-668	chr12: 109734732-109734797 [+]
				mmu-mir-485	chr12: 109734902-109734974 [+]
				mmu-mir-453	chr12: 109735619-109735700 [+]
				mmu-mir-154	chr12: 109738433-109738498 [+]
				mmu-mir-496a	chr12: 109739119-109739197 [+]
				mmu-mir-377	chr12: 109740510-109740577 [+]

				mmu-mir-541	chr12: 109742409-109742498 [+]
				mmu-mir-409	chr12: 109743158-109743236 [+]
				mmu-mir-412	chr12: 109743289-109743368 [+]
				mmu-mir-369	chr12: 109743418-109743496 [+]
				mmu-mir-410	chr12: 109743715-109743795 [+]
				mmu-mir-3072	chr12: 109747878-109474960 [+]
mmu-mir-337	mmu-mir-337-5p mmu-mir-337-3p	mir-337		mmu-mir-337	chr12: 109585789-109585885 [+]
mmu-mir-3544		mir-3544		mmu-mir-3544	chr12: 109585813-109585873 [-]
mmu-mir-540		mir-540		mmu-mir-540	chr12: 109586080-109586146 [+]
mmu-mir-540		mir-540		mmu-mir-665	chr12: 109586314-109586407 [+]
mmu-mir-127	mmu-mir-127-5p mmu-mir-127-3p	mir-127		mmu-mir-3070-1	chr12: 109587943-109588031 [+]
				mmu-mir-3070-2	chr12: 109588592-109588680 [+]
mmu-mir-434	mmu-mir-434-5p mmu-mir-434-3p	mir-434		mmu-mir-431	chr12: 109590447-109590537 [+]
				mmu-mir-433	chr12: 109591715-109591838 [+]
mmu-mir-431	mmu-mir-431-5p	mir-431		mmu-mir-127	chr12: 109592846-109592915 [+]
mmu-mir-136	mmu-mir-136-3p	mir-136		mmu-mir-434	chr12: 109594506-109594599 [+]

	mmu-mir-136-5p		mmu-mir-432	chr12: 109594956-109595030 [+]
mmu-mir-3071		no family	mmu-mir-3071 mmu-mir-136	chr12: 109595318-109595397 [-] chr12: 109595327-109595388 [+]
mmu-mir-19b-1 mmu-mir-19b-2	mmu-mir-19b-3p	miR-19	mmu-miR-17 mmu-miR-18a mmu-miR-19a mmu-miR-20a mmu-miR-19b-1 mmu-miR-92a-1	chr14: 115043671-115043754 [+] chr14: 115043851-115043946 [+] chr14: 115044000-115044081 [+] chr14: 115044157-115044263 [+] chr14: 115044305-115044391 [+] chr14: 115044427-115044506 [+]
mmu-mir-31	mmu-mir-31-5p	mir-31	mmu-mir-31	chr4: 88910557-88910662 [-]
mmu-mir-146b	mmu-miR-146b-5p	mir-146	mmu-miR-146b	chr19: 46342762-46342870 [+]
mmu-mir-21a	mmu-miR-21a-5p	mir-21	mmu-miR-21a	chr11: 86584067-86584158 [-]
mmu-mir-32	mmu-mir-32-5p	mir-32	mmu-mir-32	chr4: 56895226-56895298 [-]
mmu-mir-96	mmu-mir-96-5p	mir-96	mmu-mir-183 mmu-mir-96 mmu-mir-182	chr6: 30169668-30169737 [-] chr6: 30169446-30169551 [-] chr6: 30165918-30165992 [-]

	mmu-mir-208b	mmu-mir-208b-3p	mir-208	mmu-mir-208b	chr14: 54975700-54975776 [-]		
	mmu-mir-341	mmu-mir-341-3p	mir-341	mmu-mir-341	chr12: 109611500-109611595 [+]		
mmu-mir-1188				chr12: 109611822-109611941 [+]			
mmu-mir-370				chr12: 109618258-109618336 [+]			
mmu-mir-674	mmu-mir-674-5p	mir-674	mmu-mir-674	chr2: 117185127-117185226 [+]			
mmu-mir-184	mmu-mir-184-3p	mir-184	mmu-mir-184	chr9: 89802260-89802328 [-]			
DOWNREGULATED	mmu-mir-126a	mmu-mir-126a-3p	mir-126	mmu-mir-126a	chr2: 26591357-26591429 [+]		
		mmu-mir-126a-5p					
	mmu-mir-126b	mmu-mir-126b-3p				mmu-mir-126b	chr2: 26591363-26591420 [-]
		mmu-mir-126b-5p					
	mmu-mir-142a	mmu-mir-142a-3p	mir-142	mmu-mir-142a	chr11: 87756864-87756927 [+]		
		mmu-mir-142a-5p				mmu-mir-142b	chr11: 87756841-87756955 [-]
	mmu-mir-143	mmu-mir-143-3p	mir-143	mmu-mir-143	chr18: 61649196-61649258 [-]		
		mmu-mir-143-5p					
	mmu-mir-145a	mmu-mir-145a-5p	mir-145	mmu-mir-145a	chr18: 61647825-61647894 [-]		

	mmu-mir-145a-3p			
mmu-mir-199b	mmu-mir-199b-3p	mir-199	mmu-mir-3154	chr2: 32318265-32318343 [+]
	mmu-mir-199b-5p		mmu-mir-199b	chr2: 32318460-32318569 [+]
mmu-mir-199a-1	mmu-mir-199a-3p		mmu-mir-199a-2	chr1: 162217814-162217923 [+]
mmu-mir-199a-2	mmu-mir-199a-5p	mmu-mir-214	chr1: 162223368-162223477 [+]	
mmu-mir-10a	mmu-mir-10a-5p	mir-10	mmu-mir-10a	chr11: 96317165-96317274 [+]
mmu-mir-146a	mmu-mir-146a-5p	mir-146	mmu-mir-146a	chr11: 43374397-43374461 [-]
mmu-mir-497a	mmu-mir-497a-5p	mir-497	mmu-mir-497b	chr11: 70234692-70234816 [-]
mmu-mir-497b			mmu-mir-497a	chr11: 70234717-70234800 [+]
mmu-mir-195a	mmu-mir-195a-5p	mir-15	mmu-mir-195a	chr11: 70235042-70235135 [+]
mmu-mir-335	mmu-mir-335-5p	mir-335	mmu-mir-335	chr6: 30741299-30741396 [+]
mmu-mir-365-1	mmu-mir-365-3p	mir-365	mmu-mir-193b	chr16: 13449523-13449601 [+]
mmu-mir-365-2			mmu-mir-365-1	chr16: 13453840-13453926 [+]
mmu-mir-150	mmu-mir-150-5p	mir-150	mmu-mir-150 mmu-mir-5121	chr7: 45121757-45121821 [+] chr7: 45126918-45126991 [-]]
mmu-mir-181a-1	mmu-mir-181a-5p	mir-181	mmu-mir-181a-1	chr1: 137966455-137966541 [+]

mmu-mir-181a-2			mmu-mir-181a-2	chr2: 38852735-38852810 [+]
mmu-mir-23a	mmu-mir-23a-3p	mir-23	mmu-mir-23a	chr8: 84208518-84208592 [+]
mmu-mir-27a	mmu-mir-27a-3p	mir-27	mmu-mir-27a	chr8: 84208672-84208758 [+]
	mmu-mir-3074-5p	mir-3074	mmu-mir-24-2	chr8: 84208815-84208921 [+]
			mmu-mir-3074-2	chr8: 84208825-84208907 [-]
mmu-mir-144	mmu-mir-144-3p	mir-451	mmu-mir-144	chr11: 78073005-78073070 [+]
mmu-mir-451a	mmu-mir-451a		mmu-mir-451b	chr11: 78073170-78073241 [-]
mmu-mir-451b			mmu-mir-451a	chr11: 78073170-78073241 [+]
mmu-mir-222	mmu-mir-222-3p	mir-221	mmu-mir-222	chrX: 19146893-19146971 [-]
mmu-mir-221	mmu-mir-221-3p		mmu-mir-221	chrX: 19146294-19146388 [-]
mmu-mir-223	mmu-mir-223-3p	mir-223	mmu-mir-223	chrX: 96242817-96242926 [+]
mmu-mir-34b	mmu-mir-34b-5p	mir-34	mmu-mir-34b	chr9: 51103562-51103645 [-]
mmu-mir-34c	mmu-mir-34c-5p		mmu-mir-34c	chr9: 51103034-51103110 [-]
mmu-mir-3065		mir-3065	mmu-mir-3065	chr11: 120014767-120014853 [+]
	mmu-mir-338-3p	mir-338	mmu-mir-338	chr11: 120014765-120014862 [-]

	mmu-mir-140	mmu-mir-140-3p mmu-mir-140-5p	mir-140	mmu-mir-140	chr8: 107551244-107551313 [+]
		mmu-mir-187-3p	mir-187	mmu-mir-187	chr18: 24429110-24429170 [-]

* Clusters of upregulated miRs are almost entirely included within 40kb chromosomal area 12qf1: 109,709,060-109,747,9 (also illustrated in **Figure 3C**).

A heatmap of deregulated miRs outlining expression profiling in mouse NSCLC tissues is illustrated in **Figure 3A**. 73 hairpin forms of premature miRs distinguished NSCLC from normal lung tissue in mice, which are considered useful markers in correlation tests between human and mouse NSCLC biological models.




Figure 3. (A) Heatmap of mature mmu-miR profile comparisons between mouse NSCLC and normal lung tissue. Each column represents an RNA sample, and each row represents a single miR. NLT: Normal Lung Tissue (Sample 1 to 4), NSCLC_2A-4B: RNA samples originating from different mice

with Non-Small Cell Lung Carcinoma (NSCLC). (B) Heatmap presenting differentially expressed mature forms of hsa-miRs derived from human cell lines A549 and H460 compared to normal epithelial cells BEAS-2B. The A and B sample types refer to the technical replicates used in the NGS analysis. The color scale in both heatmaps shows the relative miR expression level in certain slide: green indicates high relative expression levels; red indicates low relative expression levels. (C) Mouse chromosomal location 12qf1 [UCSC genome browser on Mouse (GRCm38/mm10)] encompassing miR clusters overexpressed in NSCLC tissue (Table 2). miRs in dark green are detected in our study as significantly upregulated, miRs in light green are detected but not differentially expressed with statistical significance (compared to normal lung tissue) and black are miR species below limit of detection.

Of great interest was the fact that the vast majority of upregulated mmu-miR species were assigned to a specific area of mouse chromosome 12 [(UCSC genome browser on Mouse (GRCm38/mm10), 12qf1: 109,709,060-109,747,960] (Figure 3C), suggesting a genomic expansion of this chromosomal region or exceptional deregulation of transcription across this genomic area. More distant regions of chromosome 12 were also found to produce higher levels of miR species (chr12: 109585789-109595388 and chr12:109611500-109618336, Table 2) in mouse NSCLC tissue (not shown in Fig. 3C). Relative quantification of miRs derived from this chromosomal location, suggest that transcription starts from miR promoter regions across the forward strand of DNA however, RNA polymerase attenuates transcriptional efficiency since miR counts of each cluster are with a descending order. This phenomenon is color-coded and presented in Figure 3C, where miRs with the highest and significantly differentiated expression are highlighted in dark green, gradation to light green represents miRs upregulated but not statistically significant and finally black-colored miRs were not detected by NGS analysis.

3.3. Altered expression profiles of human miRs not related to LRF/ ZBTB7A transcription factor

Human miR (hsa-miR) expression levels were derived from NGS and up/downregulated species were analyzed by bioinformatics analysis as presented in materials and methods. A heatmap of the differentially expressed miRs in NSCLC cell lines (A549 and H460) is illustrated in Figure 3B and summarized in Table 3. Reads with counts lower than 1000 were discarded. Differentially expressed miRNAs were considered those with an adjusted p-value <0.05 and a log₂fold change cutoff of ± 1 . Additionally, hsa-miR families, with similar seed sequences and chromosomal locations of hsa-miR clusters lying within the same genomic region are listed in Table 3. Families of commonly upregulated miRs between A549 and H460 were miR-34, let-7 and miR-374, and accordingly downregulated families were miR-205 and miR-8. Moreover, miR-10 family members were upregulated in A549 and downregulated in H460 cells. Common members of miR-8 family, detected in both mouse and human NSCLC samples were up- or downregulated in reverse way. MiR-10 family in mice was downregulated, presenting the same trend as H460 cell line.

Significantly deregulated miRs of the human NSCLC cell lines compared to the human bronchial epithelial cell line BEAS-2B, were the following:

MiR-let-7i hairpin and mature hsa-let-7i-5p were overexpressed in NSCLC cell lines. In particular, hairpin and mature forms of hsa-let-7e and hsa-let-7e-5p were overexpressed in A549, and hsa-let-7c and hsa-let-7c-5p were overexpressed in H460. On the contrary, A549 cells were characterized by downregulation of hsa-let-7c-5p and hsa-let-7d-5p. Hairpin hsa-miR-374a and its corresponding mature form (hsa-miR-374a-5p) were also overexpressed in both A549 and H460 cell lines. Another essential miRNA, miR-34a, the first miRNA investigated in a clinical trial for solid tumors restoration [35], was upregulated as hairpin and mature (hsa-miR-34a-5p) in both A549 and H460 cells. Hairpin hsa-miR-200a, hsa-miR-200c and hsa-miR-141 along with mature forms of hsa-miR-200a-3p, hsa-miR-200c-3p and hsa-141-3p (members of mir-8 mammalian family), showed decreased levels of expression in both A549 and H460 cell lines. Finally, both human NSCLC cell lines (A549 and H460) showed a significant decrease in hsa-miR-205 (hairpin form) and hsa-miR-205-5p (mature form). Other miR molecules detected in this study either in mouse or human cells are within the list of compiled validated miRs with important diagnostic value [36].

A cluster encompassing hsa-miR-99b-5p, hsa-miR-125a-5p and hsa-let-7e-5p, located on chromosome 19, was found to be elevated only in A549 cells. These miR species derive from the same precursor RNA and although belong to the same cluster, are in separate miR families with diverse biological functions.

The same observation regarding the presence of miR species constituting a cluster applies to human samples as well as observed in mouse upregulated miR clusters of chromosome 12. All members of the same miR cluster are present (**Supplementary Tables S2 A-D**), but only subsets of the each miR cluster reach a statistical significance of deregulation. Only miR species that were depicted by bioinformatics analysis are presented in **Table 3**.

Table 3. Hairpin and mature deregulated human miRs found by NGS analysis with the respective family and cluster, according to miRBase. Chromosomal locations refer to miR clusters.

	A549 vs BEAS-2B					H460 vs BEAS-2B				
	miR hairpin	Mature miR	miR family	miR cluster	Chromosomal location	miR hairpin	Mature miR	miR family	miR cluster	Chromosomal location
UPREGULATED	hsa-mir-34a	hsa-mir-34a-5p	mir-34	hsa-mir-34a	chr1: 9151668-9151777 [-]	hsa-mir-7-1 hsa-mir-7-2 hsa-mir-7-3	hsa-mir-7-5p	mir-7	hsa-mir-7-5p	chr9: 83969748-83969857 [-]
	hsa-mir-23b		mir-27	hsa-mir-23b	chr9: 95085208-95085304 [+]	hsa-mir-182	hsa-mir-182-5p	mir-182	hsa-mir-183 hsa-mir-96 hsa-mir-182	chr7: 129774905-129775014 [-] chr7: 129774692-129774769 [-] chr7: 129770383-129770492 [-]
	hsa-mir-27b	hsa-mir-27b-3p		hsa-mir-3074 hsa-mir-24-1	chr9: 95086014-95086094 [-] chr9: 95086021-95086088 [+]	hsa-mir-3529	hsa-mir-3529-3p	mir-3529	hsa-mir-3529 hsa-mir-7-2 hsa-mir-1179	chr15: 88611847-88611924 [-] chr15: 88611825-88611934 [+] chr15: 88608107-88608197 [+]
	hsa-mir-21	hsa-mir-21-5p hsa-mir-21-3p	mir-21	hsa-mir-21	chr17: 59841266-59841337 [+]	hsa-mir-155	hsa-mir-155-5p	mir-155	hsa-mir-155	chr21: 25573980-25574044 [+]
	hsa-mir-374a	hsa-mir-374a-5p	mir-374	hsa-mir-374a hsa-mir-545	chrX: 74287286-74287357 [-] chrX: 74287104-74287209 [-]	hsa-mir-374a	hsa-mir-374a-5p	mir-374	hsa-mir-374a hsa-mir-545	chrX: 74287286-74287357 [-] chrX: 74287104-74287209 [-]

	hsa-mir-99b	hsa-mir-99b-5p	mir-10	hsa-mir-99b	chr19: 51692612-51692681 [+]	hsa-mir-148b	hsa-mir-148b-3p	mir-148	hsa-mir-148b	chr12: 54337216-54337314 [+]
	hsa-mir-125a	hsa-mir-125a-5p		hsa-let-7e	chr19: 51692786-51692864 [+]	hsa-let-7i	hsa-let-7i-5p	let-7	hsa-let-7i	chr12: 62603686-62603769 [+]
	hsa-let-7e	hsa-let-7e-5p		hsa-mir-125a	chr19: 51693254-51693339 [+]	hsa-let-7c	hsa-let-7c-5p		hsa-let-7c	chr21: 16539828-16539911 [+]
	hsa-let-7i	hsa-let-7i-5p	let-7	hsa-let-7i	chr12: 62603686-62603769 [+]	hsa-mir-34a	hsa-mir-34a-5p	mir-34	hsa-mir-34a	chr1: 9151668-9151777 [-]
	hsa-mir-182	hsa-mir-182-5p	mir-182	hsa-mir-183	chr7: 129774905-129775014 [-]	hsa-mir-126		mir-126	hsa-mir-126	chr9: 136670602-136670686 [+]
				hsa-mir-96	chr7: 129774692-129774769 [-]					
				hsa-mir-182	chr7: 129770383-129770492 [-]					
						hsa-mir-25		mir-25	hsa-mir-106b	chr7: 100093993-100094074 [-]
									hsa-mir-93	chr7: 100093768-100093847 [-]
									hsa-mir-25	chr7: 100093560-100093643 [-]
						hsa-mir-1307		mir-1307	hsa-mir-1307	chr10: 103394253-103394401 [-]
						hsa-mir-423		mir-423	hsa-mir-423	chr17: 30117079-30117172 [+]
						hsa-mir-3184			hsa-mir-3184	chr17: 30117086-30117160 [-]
							hsa-mir-138-5p	mir-138	hsa-mir-138	chr3: 44114212-44114310 [+]
							hsa-mir-196a-5p	mir-196	hsa-mir-196a	chr17: 48632490-48632559 [-]
DOWNR	hsa-mir-205	hsa-mir-205-5p	mir-205	hsa-mir-205	chr1: 209432133-209432242 [+]	hsa-mir-205	hsa-mir-205-5p	mir-205	hsa-mir-205	chr1: 209432133-209432242 [+]

hsa-mir-200a	hsa-mir-200a-3p	mir-8	hsa-mir-200b	chr1: 1167104-1167198 [+]	hsa-mir-221	hsa-mir-221-3p	mir-221	hsa-mir-222	chrX: 45747015-45747124 [-]
hsa-mir-200c	hsa-mir-200c-3p		hsa-mir-200a	chr1: 1167863-1167952 [+]				hsa-mir-221	chrX: 45746157-45746266 [-]
			hsa-mir-429	chr1: 1169005-1169087 [+]				hsa-mir-222	hsa-mir-222-3p
hsa-mir-141	hsa-mir-141-3p		hsa-mir-200c	chr12: 6963699-6963766 [+]				hsa-mir-141	hsa-mir-141-3p
		let-7	hsa-mir-141	chr12: 6964097-6964191 [+]	hsa-mir-200c	hsa-mir-200c-3p	mir-8	hsa-mir-141	chr12: 6964097-6964191 [+]
hsa-let-7c	hsa-let-7c-5p		hsa-mir-99a	chr21: 16539089-16539169 [+]	hsa-mir-200a	hsa-mir-200a-3p		hsa-mir-141	chr12: 6964097-6964191 [+]
			hsa-let-7c	chr21: 16539828-16539911 [+]	hsa-mir-100	hsa-mir-100-5p	mir-10	hsa-mir-100	chr11: 122152229-122152308 [-]
hsa-let-7d	hsa-let-7d-5p		hsa-let-7a-1	chr9: 94175957-94176036 [+]	hsa-mir-100	hsa-mir-100-5p		hsa-mir-10526	chr11: 122152103-122152156 [-]
		mir-17	hsa-let-7f-1	chr9: 94176433 [+]	hsa-mir-15a-5p	mir-15	mir-15	hsa-let-7a-2	chr11: 122146522-122146593 [-]
			hsa-let-7d	chr9: 94178834-94178920 [+]				hsa-mir-15a	chr13: 50049201 [-]
	hsa-mir-20a-5p		hsa-mir-17	chr13: 91350605-91350688 [+]	hsa-mir-16-1	chr13: 50048973-50049061 [-]			
			hsa-mir-18a	chr13: 91350751-91350821 [+]	hsa-mir-23a	chr19: 13836587-13836659 [-]			
			hsa-mir-19a	chr13: 91350891-91350972 [+]	hsa-mir-27a	chr19: 13836440-13836517 [-]			
			hsa-mir-20a	chr13: 91351065-91351135 [+]	hsa-mir-24-2	chr19: 13836287-13836359 [-]			
			hsa-mir-19b-1	chr13: 91351192-91351278 [+]	hsa-mir-130a	chr11: 57641198-57641286 [+]			
			hsa-mir-92a-1	chr13: 91351314-91351391 [+]	hsa-mir-21-3p	chr17: 59841266-59841337 [+]			

hsa-mir-15a	hsa-mir-15a-5p	mir-15	hsa-mir-15a hsa-mir-16-1	chr13: 50049119-50049201 [-] chr13: 50048973-50049061 [-]
	hsa-mir-454-3p	mir-454	hsa-mir-454	chr17: 59137758-59137872 [-]
	hsa-mir-378a-3p	mir-378	hsa-mir-378a	chr5: 149732825-149732890 [+]

3.4. Human and mouse miRs targeting LRF/ZBTB7A

Abnormal levels of Zinc-Finger/BTB-Domain-Containing Protein family members, such as LRF/ZBTB7A in malignant cell lines and tissues provide valuable insights into upstream signaling pathways/molecules and molecular mechanisms underlying their roles in genome integrity, cell cycle checkpoint obstruction and interacting partners. LRF/ZBTB7A has been characterized as an epigenetic regulator and a contingent factor orchestrating expression of non-coding RNA species [12,13]. In our analysis, ZBTB7A expression levels were found comparable and equally elevated in lung adenocarcinoma of mouse and human origin, while significantly lower ZBTB7A expression levels were obtained in H460 large cell lung carcinoma cells. **Table 4** lists mouse and human miRs either predicted with miRDB [37] or reported in literature to target ZBTB7A; results obtained from our study are also included.

Among members of the miR-10 mammalian family, our results showed downregulation of hsa-miR-100-5p (**Table 3**), considered as a direct suppressor of ZBTB7A as well as decreased ZBTB7A-mRNA levels in H460 cell line. Among mouse NSCLC samples, mmu-miR-10a-5p (**Table 2**) was significantly downregulated. Some more distant miR species of the same family, namely miR-99a/b, miR-100 and miR-125, are encoded from other genetic loci than Hox clusters [38] and imply potential mutual gene targets. Human A549 showed upregulation of hsa-miR-99b-5p and hsa-miR-125a-5p. All mentioned miR species belong to miR-10 family sharing similar seed sequences and implying similar functions and gene targets. Supportive evidence comes from studies in mice which report that *Zbtb7a* is identified as a direct target for mmu-miR-125a [39].

Moreover, A549 human cell line displayed downregulation of hsa-miR-20a-5p (**Table 3**), member of the miR-17 mammalian family and miR17/92 cluster, which has been reported to support development and progression of lung cancer in humans [40], whereas in mouse embryonic cells mmu-miR-20a overexpression contributes to cell senescence assisted by the direct ZBTB7A and E2F1 downregulation accompanied by p16 upregulation [41]. Another cooperation of miR-15a (member of miR-15 mammalian family) and ZBTB7A that has been predicted by miRDB [37], was also supported by our analysis, since hsa-miR-15a-5p was downregulated in both A549 and H460 cell lines (**Table 3**). In mouse NSCLC samples, mmu-miR-195a-5p, member of the same family (miR-15) was also downregulated. Another downregulated miR, namely mmu-miR-181a-5p was predicted to target *zbtb7a* and was also detected in our sets of deregulated mmu-miR species (**Table 2**). Hsa-miR-148b-3p, is upregulated only in H460 cells in the present study and has also been predicted to target ZBTB7A (**Table 3**). MiR-148b-3p belongs to the miR-148/-152 family members (miR-148a, miR-148b, and miR-152), which have been associated with poor overall survival in NSCLC. Drug cocktails including metformin and cisplatin promote upregulation of miR-148/-152 family suggesting these molecules as potential targets for therapy of lung cancer [42].

Other interesting associations between miRNA species and ZBTB7A are presented in **Table 4**, which are highlighted in relevant literature but neither were apparent among significantly altered miR species in our study nor they were predicted by miRDB [37]. Hsa-miR-577 has been shown to be suppressed in NSCLC and this reduction was associated with sponge effects of the elevated circular

non-coding RNA circ_0016760, derived from the same human tissues. Circ_0016760 was also predicted to modulate hsa-miR-577 expression and downregulation via employment of starBase 3.0 bioinformatics tool, further promoting expression of the *ZBTB7A* (target of hsa-miR-577) gene and NSCLC progression [43]. Quantitative PCR analysis from total RNA derived from NSCLC tumor and paired adjacent normal lung tissues showed increased levels of hsa-miR-520e in NSCLC. Hsa-miR-520e was suggested to target the 3'UTR of *ZBTB7A*-mRNA and to be implicated in tumor cell growth, invasion and migration via modulation of Wnt signaling in A549 cells [44]. Another mammalian miR, hsa-miR-106b was shown to directly target the 3' UTR of *ZBTB7A*-mRNA and to alleviate its expression levels in HEK-293T cells [45]. Finally, the 3'UTR of *ZBTB7A*-mRNA sequence encompasses a putative binding site for miR-144-3p. In bladder cancer miR-144-3p suppresses malignancy via targeting and decreasing *ZBTB7A*, having an inverse correlation with HIC1/ZBTB29 (Hypermethylated in cancer 1/Zinc Finger And BTB Domain-Containing Protein 29) gene expression [46], another member of the Zinc-Finger/BTB-Domain-Containing Proteins. In lung cancer increased expression of *ZBTB7A* has been shown to inactivate the TP53 (Tumor Protein P53) by increasing the levels of MDM2 (MDM2 Proto-Oncogene, E3 Ubiquitin Protein Ligase), frequently overexpressed in this type of malignancy. In addition, a significant number of NSCLC tissues examined displayed 2-5-fold amplification of *ZBTB7A* chromosomal locus 19p13.3, accompanied by increased mRNA and protein levels strongly suggesting that the amplification process may have functional consequences [47].

Table 4. Targeting of *ZBTB7A* by miRs, predicted with respective scores by miRDB or reported in literature.

Chromosome	Family	miRNA	Gene target	interaction with 3'UTR	Score/REF	Results from our study
13	miR-17	hsa-miR-20a-5p	<i>ZBTB7A</i>	at 912, 1205, 1230, 4309 bp	96	A549 downregulated
19	miR-10	hsa-miR-125a-5p	<i>ZBTB7A</i>	at 547, 803, 1667, 4210 bp	81/[39]	A549 upregulated
12	miR-148	hsa-miR-148b-3p	<i>ZBTB7A</i>	at 1877, 2071 bp	50	H460 upregulated
13	miR-15	hsa-miR-15a-5p	<i>ZBTB7A</i>	at 3305 bp	65	A549 and H460 downregulated
19	miR-10	hsa-miR-100-5p	<i>ZBTB7A</i>		[48]	H460 downregulated
4	miR-577	hsa-miR-577	<i>ZBTB7A</i>		[43]	-
7	miR-17	hsa-miR-106b	<i>ZBTB7A</i>		[49]	-
17	miR-144	hsa-miR-144-3p	<i>ZBTB7A</i>		[46]	-
19	miR-520e	hsa-miR-520e	<i>ZBTB7A</i>		[44]	-

19	miR-10	mmu-miR-10a-5p	<i>Zbtb7a</i>		68	NSCLC mouse tissue downregulated
13	miR-15	mmu-miR-195a-5p	<i>Zbtb7a</i>			NSCLC mouse tissue downregulated
1 and 2	miR-181	mmu-miR-181a-1-5p and mmu-miR-181a-2-5p	<i>Zbtb7a</i>	at 2907 bp	87	NSCLC mouse tissue downregulated

3.5. Deregulated lncRNA expression and methylation levels, and lncRNA/miR functional axes in cancer state

The constant clinical needs for reliable markers of cancer development and progression places emphasis on established high-throughput approaches and molecular networking assessment, composed of molecules that either compete or jointly cooperate in cancer state. Following this route, we examined the literature for double or triple epigenetic biomarkers with the aim to unravel epigenetic networks underlying NSCLC. Our results support several previously reported and a novel combination of lncRNA/miRNA molecules with regulatory control on LRF/*ZBTB7A* expression.

MEG3-lncRNA has been detected significantly downregulated in NSCLC and reported to exhibit regulatory properties during cisplatin treatment through the control of p53 and Bcl-xl expression [50]. On the other hand, overexpression of MEG3-lncRNA is suggested to positively regulate tumor suppressor PTEN expression levels by suppressing hsa-miR-21-5p, which directly attacks PTEN. By an in vitro strategy MEG3 overexpression suppressed the migration and invasion abilities of human NSCLC PC9 and H1299 cell lines [51]. We observed upregulated levels of hsa-miR-21 hairpin structure as well as mature forms of hsa-miR-21-5p and hsa-miR-21-3p only in A549 cells combined with hypermethylation status (above 90%) of CpG island 78 suppressing the transcription of MEG3-lncRNA.

Other studies including NSCLC human samples, have shown a positive correlation between increased *H19*-lncRNA and hsa-miR-21 expression with increased tumor size and advanced tumor-node-metastasis stage, but not classification [52], providing an improved diagnostic value as a double-molecular biomarker. In our study, elevated expression of hsa-miR-21-5p was limited only in A549 cells and was accompanied by the hypermethylation status of CpG36 located upstream of *H19*-lncRNA, promoting transcriptional repression of the lncRNA.

Altered expression of *HOTAIRM1*-lncRNA has been reported in human cancers as well as its capability to promote treatment resistance [53]. *HOTAIRM1* gene is located adjacent and antisense to the transcription start site of *HOXA1* and between the neighboring *HOXA2* gene. Its transcription is initiated from the shared promoter segment embedded in CpG island 116. *HOTAIRM1*-lncRNA is highly expressed in lenvatinib-resistant hepatocellular carcinoma leading to hsa-miR-34a downregulation and autophagy activation via regulation of beclin-1 marker molecule [54]. Relevant results from our study showed undetectable levels of *HOTAIRM1*-lncRNA expression, followed by upregulation of hsa-miR-34a (hairpin and mature forms) in both A549 and H460 cells, although *HOTAIRM1* CpG island 116 was inversely methylated in human cell lines (**Figure 2E**) implying different regulatory transcriptional mechanisms rather than methylation status for this particular lncRNA.

Several other studies have revealed more pathways of cooperation between lncRNA and miRNAs. *MALAT1*-lncRNA was shown to regulate proliferation, apoptosis, migration and invasion

via the miR-374b-5p/*SRSF7* and hsa-miR-200a/*ZEB-1* axis in NSCLC [55], 56). In the present study, we failed to detect any level of expression for *MALAT1*-lncRNA, although TSS of this lncRNA transcript resides within CpG island 50 and displayed hypomethylated levels below 10%, implying an accessible promoter for transcription (**Figure 2E**). At the same time, hsa-miR-374a-5p was upregulated in both A549 and H460 cell lines, results that are in line with observations by J. Song et al [56] leading to other regulatory parameters that control *MALAT1*-lncRNA expression, apart from methylation status of CpG island 50. On the contrary, hairpin structure of hsa-miR-200a and mature hsa-miR-200a-3p were suppressed in A549 and H460 cells.

In a chronic inflammatory disease (endometriosis), high levels of *MALAT1*-lncRNA sponged hsa-miR-141-3p and promoted *NLRP3* (NLR Family Pyrin Domain Containing 3) gene expression functioning towards pyroptosis and fibrosis, characteristic signs of endometriosis [57]. Both A549 and H460 NSCLC cell lines in our investigation demonstrated repressed hsa-miR-141-3p, although *MALAT1*-lncRNA was undetectable, suggesting the existence of alternative regulatory networks relevant to different kinds of human disorder and/or alternative TSSs for *MALAT1* gene that substitute the targeted promoter. Related comprehensive studies also report that *MALAT1*-lncRNA is not detectable in A549 and H460 cells [58] confirming our results.

Upregulation of another lncRNA, *DANCR*-lncRNA, has been shown to have an oncogenic function in NSCLC by regulating hsa-miR-214-5p/*CIZ1* axis [59]. CpG island 93 at the 5' end of *DANCR*-lncRNA promoter was found hypomethylated (4-15%) in A549, H460 and BEAS-2B cells lines respectively (**Figure 2E**), but expression levels were decreased (by about 70%) only in A549 cells. Also, hsa-miR-214-5p was not detected in any of the NSCLC samples tested in this study.

Another interesting regulatory circuit between *PVT1*-lncRNA, let-7 miR family, hsa-miR-128 and the highly conserved RNA-binding oncoprotein, Lin28 responsible for posttranscriptional inhibition of let-7 biogenesis, was investigated in colorectal cancer. Upregulation of *PVT1*-lncRNA was inversely correlated with miR-128 expression and moreover, *PVT1*-lncRNA targeted the Lin28/let-7 axis to promote tumorigenesis [60]. However, in our study different members of let-7 miR family were either up or downregulated in human NSCLC cell lines and furthermore, hsa-miR-128 was not detected among deregulated miR species. Also, *PVT1*-lncRNA has been reported to promote cancer proliferation, invasion and migration in NSCLC via regulating several human miR species. Among them hsa-miR-148/*RAB34*, hsa-miR-145-5p/*ITGB8* (Integrin Subunit Beta 8) and hsa-miR-361-3p/*SOX9* (SRY-Box Transcription Factor 9) axis are known to be modulated by *PVT1*-lncRNA [61–63], providing evidence for combinational function of epigenetic mechanisms underlying NSCLC progression. In the present study hsa-miR-148b-3p was upregulated only in H460 cells combined with high (up to 70%) methylation profiles of CpG island 94 of *PVT1*-lncRNA and downregulation of its expression. Related results from A549 cells displayed lower methylation status (below 40%) for CpG island 94 along with upregulated expression signatures of *PVT1*-lncRNA and undetectable levels of hsa-miR-148b-3p. Apparently, hsa-miR-148b-3p/*PVT1*-lncRNA/*ZBTB7A*-mRNA represents an interesting network derived from our study, which is introduced for the first time in literature. Furthermore, describes the significantly repressed *ZBTB7A* levels in H460 (large cell lung carcinoma) cell line in contrast to all other NSCLC (adenocarcinoma) human and mouse samples tested. All reported interactions in human samples between *ZBTB7A* and non-coding RNAs (miRs and lncRNAs) are illustrated in **Figure 4**. Also, Differentially expressed miRs and lncRNAs derived from the present study could be used as diagnostic markers for LUAD, as shown in **Figure 5** using data from the KMplot pan-cancer miR dataset (<http://kmplot.com>) [64].




Figure 4. Interplay of lncRNA/miRNAs and ZBTB7A- mRNA in human NSCLC KRAS mutant cell lines A549 and H460, derived from the present study.




Figure 5. miR and lncRNA species produced by this study as biomarkers of lung adenocarcinoma. Kaplan-Meier survival plots with median overall survival (OS), hazard ratios (HR) with 95% confidence interval, and univariate log-rank probability values (P) from 513 patients with lung adenocarcinoma, stratified into low (black) and high (red) miRNAs and lncRNAs expression by the optimal cut-offs indicated. Data from Kmplot (<http://kmplot.com>).

4. Discussion

Our study is an attempt to deepen our understanding of epigenetic events discriminating NSCLC subtypes on the epigenetic level and inspire new directions for the design and testing of agents interfering with the cell epigenome.

To that end, we have comprehensively mapped the functional miRNA and lncRNA landscape of human (A549 and H460) and mouse (experimentally developed LUAD) NSCLC models and correlated current results with LRF/*ZBTB7A* expression. LRF is a BTB-ZF (broad-complex, tramtrack and bric-à-brac-zinc finger) protein, strongly implicated in epigenetic regulation of human genes including ncRNAs [3, 4]. Interestingly, *ZBTB7A* gene (transcribing LRF) was found to be differentially expressed in the two NSCLC subtypes that we studied: *ZBTB7A* was overexpressed in human A549 and mouse lung adenocarcinoma samples, but significantly underexpressed in H460 large cell carcinoma cell line (**Figure 2C-D**), suggesting an exceptional role of *ZBTB7A* expression signature in the large cell lung carcinoma. Another important result was also the upregulation of hsa-miR-148b-3p only in H460 cell line, which is predicted to target *ZBTB7A*-mRNA (**Table 4**) among other gene targets, and it is sponged by the *H19*- and *PVT1*-lncRNAs [48-50]; these traits render hsa-miR-148b-3p an attractive candidate regarding the differential regulation of *ZBTB7A* expression in lung large cell carcinoma. Its capability of attacking also DNMTs with other members of the miR-148/-152 family makes this molecule an essential epigenetic regulator and a novel potential target for lung cancer treatment [50]. The repressed *PVT1*-lncRNA levels that were detected in H460 cells are suggested to contribute to the observed hsa-miR-148b-3p upregulation and *ZBTB7A* downregulation, signifying the regulatory axis miR-148b-3p/*PVT1*-lncRNA/*ZBTB7A*-mRNA, that merits further research (**Figure 4**) and verification in human samples.

With the view of deregulated miR families associated with LRF TF (all listed in **Table 4**), our results showed downregulation of both hsa-miR-100-5p, member of the mammalian miR-10 family (**Table 3**) and *ZBTB7A*-mRNA levels in H460 cell line (**Figure 2D**). Relative lower expression of hsa-miR-100, a direct suppressor of *ZBTB7A*, has been positively correlated with lymph node metastasis and larger tumor size in gastric cancer implying another emerging cooperation between miRs and transcription factors [43]. Also, A549 human cell line displayed downregulation of hsa-miR-20a-5p (**Table 3**), member of the miR-17 mammalian family and miR17/92 cluster, implicated in lung cancer in humans [46]. Hsa-miR-15a-5p, member of miR-15 mammalian family was downregulated in both A549 and H460 cell lines (**Table 3**) and mmu-miR-195a-5p, member of the same family was also downregulated (**Table 2**). Hsa-miR-148b-3p, was upregulated only in H460 cells, which belongs to the miR-148/-152 family members (miR-148a, miR-148b, and miR-152), and its overexpression has been associated with longer overall survival of patients with NSCLC [48, 49]. Other, deregulated miR families and species either reported in research studies or predicted by miRDB [42], are discussed in the results section.

Expanding on this track, relevant lncRNA transcripts produced in NSCLC human cell lines against the physiological human cells BEAS-2B, were retrieved. MEG3- and *PVT1*-lncRNAs levels of expression were reduced, mainly in H460 cell line. *H19*-lncRNA showed insignificant differences in expression levels, *DANCR*-lncRNA was reduced only in A549, whereas *MALAT1*- and *HOTAIRM1*-lncRNAs were undetected in all cell lines tested. Methylation levels in CpG islands flanking 5' end of lncRNA genes were very high (over 80%) in all lncRNAs tested in H460 cells except from *MALAT1*- and *DANCR*-lncRNAs. A549 and BEAS-2B cells displayed comparable methylation levels (**Figure 3E**) among CpG islands studied. A detailed discussion of our findings in relation to the literature and to the miRs detected is presented in the corresponding paragraph of the results section.

Significantly deregulated miR families between human and mouse NSCLC samples, detected by NGS and consequent bioinformatics analysis, were members of the mammalian family miR-21 namely, mmu-miR-21a and mmu-miR-21a-5p as well as hsa-miR-21 and hsa-miR-21-3p hairpin and mature forms, which were found upregulated in both NSCLC mouse tissue and A549 cell line (**Figure 3A and 3B, Tables 2 and 3**). MiR-21 involvement in NSCLC tumorigenesis and drug resistance has already been documented in humans [26, 27]. On the other hand, members of mammalian families miR-221, miR-222 and miR-27 (hairpin and mature structures) were significantly reduced in mouse NSCLC and human H460 cells. In humans, hsa-miR-221 has been proposed as a marker for early diagnosis and NSCLC screening [28], the *HMGA1*/miR-222 signaling axis to regulate AKT and to act as an effective tumor suppressor pathway in lung cancer cells [29], whereas miR-27a has been shown to negatively regulate *EGFR* in NSCLC [30]. Other identified miR subgroups with

differential expression patterns between NSCLC samples of human and mouse origin were members of family miR-34 (mmu-miR-34b and mmu-miR-34c), which were found downregulated in mouse NSCLC, while in both human NSCLC cell lines hsa-miR-34a and hsa-miR-34a-5p species, were upregulated. Furthermore, in mouse NSCLC samples, all members of the family miR-8, namely mmu-miR-141, mmu-miR-200a, mmu-miR-200b, mmu-miR200c and mmu-miR-429 were upregulated; however, all corresponding hsa-miRs of the same family, apart from miR-200b and miR-429, were downregulated in both A549 and H460 cell lines. MiR-8 family includes highly conserved miRs and some particular species are reported to be implicated in tumor growth and progression [31, 32].

Concludevily, miR collections among human and mouse samples were highly divergent, suggesting variability in NSCLC stage and subtype, and highlighting the diverse pathways disrupted in NSCLC, further to the extended biological variations existing between origins of these mammals. A prominent connection between human NSCLC cell lines and mouse NSCLC tissue samples was the detection of deregulated miRs comprising the mammalian miR-8, miR-10 and miR-15 family members, encompassing miR species with identical seed sequences and mutual mRNA targets. In this context, deregulated expression levels of miR-10 and miR-15 family members represent a very interesting observation since they typically target *ZBTB7A*-mRNA (**Table 4**). Another important observation was that the upregulated miR species in mouse NSCLC were mainly transcribed from the 12qf1 chromosomal region encompassing a large number of miR clusters (**Table 2, Figure 3C**). Quantification analysis on miRs' expression levels based on read counts per miR led to an interesting result. Mmu-miR clusters transcribed from this chromosomal area displayed gradually decreased read counts which can be attributed to the attenuation effect of RNA polymerase during transcriptional elongation but raised also intriguing research perspectives for the transcriptional regulation of this chromosomal area during the NSCLC development and progression in mice.

Direct comparisons of deregulated miR sets between human NSCLC cell lines and the physiological human bronchial epithelial cell line BEAS-2B, showed overexpressing values for miR-let-7i (hairpin and mature forms), known to have as direct target *BAG-1* (Bcl-2 associated athanogene-1)-mRNA, a member of the BAG-family of co-chaperones, with motility, differentiation and apoptosis properties. However, high levels of *XIST*- lncRNA represses hsa-miR-let-7i expression, thus preventing *BAG-1* inhibition in A549 cells [33]. Other miR-let-7 family members were significantly deregulated also, which have been reported to regulate the expression of genes involved in cell proliferation and cell cycle and to modulate GTPase-KRAS expression in malignancy [34, 35] but nevertheless, showed uncommon patterns of expression between A549 and H460 cell lines. Hsa-miR-374a-5p and hsa-miR-34a-5p were also overexpressed in both A549 and H460 cell lines. Hsa-miR-374a-5p has been associated with the *TGFA* (transforming growth factor-alpha) gene silencing, leading to significant inhibitory effects on proliferation, migration and invasion of malignancy [36], whereas high expression of hsa-miR-34a and hsa-miR-34c in plasma and tumor tissue of 196 NSCLC patients has been associated with prolonged overall survival and disease-free survival [38].

Decreased levels of expression in both A549 and H460 cell lines compared to BEAS-2B cells showed members of the mir-8 and mir-205 mammalian families. MiR-8 family consists of evolutionarily conserved miRNAs in two human genomic loci, miR-200b/200a/429 on chromosome 1 and miR-200c/141 on chromosome 12 and acquires significant tumor-suppressive roles in a wide array of human cancers [39]. MiR-200c/141 species deficiency promotes tumor growth and progression and also increases the metastasis frequency by recapitulating the desmoplastic lung tumor microenvironment [32]. Concerning mir-205 family members, hsa-miR-205-5p has been recently characterized as a specific prognostic biomarker, mainly for squamous cell lung carcinoma, whereas serum levels of this miR have been documented as a valuable biomarker for lung cancer diagnosis [40]. Kaplan Meier plotting tool revealed strong correlation between some of the miR and lncRNA species detected by this study and median overall survival (**Figure 5**) in LUAD.

5. Conclusions

This study offered a unique opportunity to study the various epigenetic aspects of *KRAS*-mutant NSCLC in established biological models, comprised of immortalized human cell lines (A549 and H460) and urethane-treated FVB mice.

Our study highlighted variable epigenetic features and uncovered significant relationships between different epigenetically motivated molecular biomarkers, mainly ncRNAs and TFs. Several TFs have been proved to control ncRNAs' expression in a tissue-specific and highly-selective manner; LRF encoded by *ZBTB7A* gene holds an outstanding position previously documented. Results presented highlight considerations and limitations arising from the variation displayed by the experimental models utilized in NSCLC research and prospects for new applications deriving from the epigenetic view.

Supplementary Materials: The following supporting information can be downloaded at the website of this paper posted on Preprints.org, Supplementary table S1: Primer sets for Pyrosequencing (CpG) assays and qPCRs; Supplementary excel tables 2A-2D: Hairpin and mature miRs derived from A549 and H460 human cell lines; Supplementary excel table 3S: Hairpin and mature miRs derived from mouse tissues.

Author Contributions: Magda Spella: Investigation, Data curation, Writing original draft. Eleftherios Bochalos, Katerina Athanasopoulou: NGS performance, Validation, Data curation. Argyri Chroni, Irene Dereki, Giannoula Ntaliarda: Cell cultures, mice manipulations, qPCRs, Data curation. Ifigeneia Makariti, Georgios Psarias, Caterina Constantinou: Methodology, Formal analysis, Investigation. Vasiliki Chondrou: Supervision, experimental design. Argyro Sgourou: Project administration, Writing – review & editing, Funding acquisition. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the 80250 (ELKE_EAP) grant of the Hellenic Open University (A.S.) and the General Secretariat for Research and Innovation and Hellenic Foundation for Research and Innovation grant 1853 (M.S.).

Institutional Review Board Statement: All animal experiments were approved a priori by the Veterinary Administration of the Prefecture of Western Greece (approval numbers 3741/16.11.2010, 60291/3035/19.03.2012, and 118018/578/30.04.2014) and conducted according to Directive 2010/63/EU (<http://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1486710385917&uri=CELEX:32010L0063>).

Informed Consent Statement: Not applicable.

Data Availability Statement: Data supporting reported results are provided as Supplementary Material.

Conflicts of Interest: Ifigeneia Makariti is financially supported by BioAnalytica SA, Biotechnology supplier company and also a member of the research team of biology HOU lab. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

1. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. *J Thorac Oncol.* 2015;10(9):1243-60.
2. Cascetta P, Marinello A, Lazzari C, Gregorc V, Planchard D, Bianco R, et al. *KRAS* in NSCLC: State of the Art and Future Perspectives. *Cancers (Basel).* 2022;14(21).
3. Horie M, Kaczkowski B, Ohshima M, Matsuzaki H, Noguchi S, Mikami Y, et al. Integrative CAGE and DNA Methylation Profiling Identify Epigenetically Regulated Genes in NSCLC. *Mol Cancer Res.* 2017;15(10):1354-65.
4. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. *Lung cancer (Amsterdam, Netherlands).* 2011;71(1):3-10.
5. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. *Nat Rev Genet.* 2002;3(6):415-28.
6. Sherafatian M, Arjmand F. Decision tree-based classifiers for lung cancer diagnosis and subtyping using TCGA miRNA expression data. *Oncol Lett.* 2019;18(2):2125-31.
7. Chen B, Gao T, Yuan W, Zhao W, Wang TH, Wu J. Prognostic Value of Survival of MicroRNAs Signatures in Non-small Cell Lung Cancer. *J Cancer.* 2019;10(23):5793-804.
8. Hu S, Yuan Y, Song Z, Yan D, Kong X. Expression Profiles of microRNAs in Drug-Resistant Non-Small Cell Lung Cancer Cell Lines Using microRNA Sequencing. *Cell Physiol Biochem.* 2018;51(6):2509-22.

9. Cortez MA, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin GA, et al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. *Mol Ther*. 2014;22(8):1494-503.
10. Ginn L, Shi L, Montagna M, Garofalo M. LncRNAs in Non-Small-Cell Lung Cancer. *Noncoding RNA*. 2020;6(3).
11. Guo Q, Wang J, Gao Y, Li X, Hao Y, Ning S, Wang P. Dynamic TF-lncRNA Regulatory Networks Revealed Prognostic Signatures in the Development of Ovarian Cancer. *Frontiers in bioengineering and biotechnology*. 2020;8:460.
12. Chondrou V, Shaukat A-N, Psarias G, Athanasopoulou K, Iliopoulou E, Damanaki A, et al. LRF Promotes Indirectly Advantageous Chromatin Conformation via BGLT3-lncRNA Expression and Switch from Fetal to Adult Hemoglobin. *International Journal of Molecular Sciences*. 2022;23(13):7025.
13. Gupta S, Singh AK, Prajapati KS, Kushwaha PP, Shuaib M, Kumar S. Emerging role of ZBTB7A as an oncogenic driver and transcriptional repressor. *Cancer letters*. 2020;483:22-34.
14. Ferrer I, Zugazagoitia J, Herberth S, John W, Paz-Ares L, Schmid-Bindert G. KRAS-Mutant non-small cell lung cancer: From biology to therapy. *Lung cancer (Amsterdam, Netherlands)*. 2018;124:53-64.
15. Kanellakis NI, Giannou AD, Pepe MAA, Agalioi T, Zazara DE, Giopanou I, et al. Tobacco chemical-induced mouse lung adenocarcinoma cell lines pin the prolactin orthologue proliferin as a lung tumour promoter. *Carcinogenesis*. 2019;40(11):1352-62.
16. Spella M, Lilis I, Pepe MA, Chen Y, Armaka M, Lamort AS, et al. Club cells form lung adenocarcinomas and maintain the alveoli of adult mice. *eLife*. 2019;8.
17. Aftabi Y, Ansarin K, Shanebandi D, Khalili M, Seyedrezazadeh E, Rahbarnia L, et al. Long non-coding RNAs as potential biomarkers in the prognosis and diagnosis of lung cancer: A review and target analysis. *IUBMB life*. 2021;73(2):307-27.
18. Chen Z, Lei T, Chen X, Gu J, Huang J, Lu B, Wang Z. Long non-coding RNA in lung cancer. *Clinica chimica acta; international journal of clinical chemistry*. 2020;504:190-200.
19. Entezari M, Ghanbarirad M, Taheriazam A, Sadrkhanloo M, Zabolian A, Goharrizi M, et al. Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2022;150:112963.
20. Fang C, Wang L, Gong C, Wu W, Yao C, Zhu S. Long non-coding RNAs: How to regulate the metastasis of non-small-cell lung cancer. *Journal of cellular and molecular medicine*. 2020;24(6):3282-91.
21. Guo T, Li J, Zhang L, Hou W, Wang R, Zhang J, Gao P. Multidimensional communication of microRNAs and long non-coding RNAs in lung cancer. *Journal of cancer research and clinical oncology*. 2019;145(1):31-48.
22. Liu T, Han C, Fang P, Zhu H, Wang S, Ma Z, et al. Long non-coding RNAs in lung cancer: implications for lineage plasticity-mediated TKI resistance. *Cellular and molecular life sciences : CMLS*. 2021;78(5):1983-2000.
23. Albarino CG, Romanowski V. Phenol extraction revisited: a rapid method for the isolation and preservation of human genomic DNA from whole blood. *Molecular and cellular probes*. 1994;8(5):423-7.
24. Vlaikou AM, Kouroupis D, Sgourou A, Markopoulos GS, Bagli E, Markou M, et al. Mechanical stress affects methylation pattern of GNAS isoforms and osteogenic differentiation of hAT-MSCs. *Biochimica et biophysica acta Molecular cell research*. 2017;1864(8):1371-81.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods*. 2001;25(4):402-8.
26. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic acids research*. 2001;29(9):e45.
27. Andrews S. FastQC: A Quality Control Tool for High Throughput Sequence Data [Online] Available online at:2010 [Available from: <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>].
28. Smith T, Heger A, Sudbery I. UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy. *Genome research*. 2017;27(3):491-9.
29. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. 2011. 2011;17(1):3.
30. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nature methods*. 2012;9(4):357-9.
31. Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. *Nucleic acids research*. 2019;47(D1):D155-d62.
32. Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years of SAMtools and BCFtools. *GigaScience*. 2021;10(2).
33. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. *Bioinformatics (Oxford, England)*. 2015;31(2):166-9.
34. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome biology*. 2014;15(12):550.

35. Hong DS, Kang YK, Borad M, Sachdev J, Ejadi S, Lim HY, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. *British journal of cancer*. 2020;122(11):1630-7.
36. Zhong S, Golpon H, Zardo P, Borlak J. miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer. *Translational research : the journal of laboratory and clinical medicine*. 2021;230:164-96.
37. Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. *Nucleic acids research*. 2020;48(D1):D127-d31.
38. Tehler D, Høyland-Kroghsbo NM, Lund AH. The miR-10 microRNA precursor family. *RNA biology*. 2011;8(5):728-34.
39. Hojo N, Tatsumi N, Moriguchi N, Matsumura A, Morimoto S, Nakata J, et al. A Zbtb7a proto-oncogene as a novel target for miR-125a. *Molecular carcinogenesis*. 2016;55(12):2001-9.
40. Zhang X, Li Y, Qi P, Ma Z. Biology of MiR-17-92 Cluster and Its Progress in Lung Cancer. *International journal of medical sciences*. 2018;15(13):1443-8.
41. Pitto L, Ripoli A, Cremisi F, Simili M, Rainaldi G. microRNA(interference) networks are embedded in the gene regulatory networks. *Cell cycle (Georgetown, Tex)*. 2008;7(16):2458-61.
42. Lee BB, Kim D, Kim Y, Han J, Shim YM, Kim DH. Metformin regulates expression of DNA methyltransferases through the miR-148/-152 family in non-small lung cancer cells. *Clinical epigenetics*. 2023;15(1):48.
43. Hao Y, Xi J, Peng Y, Bian B, Hao G, Xi Y, Zhang Z. Circular RNA Circ_0016760 Modulates Non-Small-Cell Lung Cancer Growth Through the miR-577/ZBTB7A Axis. *Cancer management and research*. 2020;12:5561-74.
44. Zhijun Z, Jinggang H. MicroRNA-520e suppresses non-small-cell lung cancer cell growth by targeting Zbtb7a-mediated Wnt signaling pathway. *Biochemical and biophysical research communications*. 2017;486(1):49-56.
45. Liang X, Zhao Q, Geng T, Luo S, He Q. MiR-106b regulates the apoptosis and tumorigenesis of hepatocellular carcinoma via targeting Zinc finger and BTB domain-containing protein 7A (Zbtb7a). *Journal of biochemical and molecular toxicology*. 2018;32(8):e22169.
46. Liu J, Chou Z, Li C, Huang K, Wang X, Li X, et al. ZBTB7A, a miR-144-3p targeted gene, accelerates bladder cancer progression via downregulating HIC1 expression. *Cancer cell international*. 2022;22(1):179.
47. Apostolopoulou K, Pateras IS, Evangelou K, Tsantoulis PK, Lontos M, Kittas C, et al. Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non-small cell lung cancer. *The Journal of pathology*. 2007;213(3):294-302.
48. Shi DB, Wang YW, Xing AY, Gao JW, Zhang H, Guo XY, Gao P. C/EBP α -induced miR-100 expression suppresses tumor metastasis and growth by targeting ZBTB7A in gastric cancer. *Cancer letters*. 2015;369(2):376-85.
49. Jiao D, Yan Y, Shui S, Wu G, Ren J, Wang Y, Han X. miR-106b regulates the 5-fluorouracil resistance by targeting Zbtb7a in cholangiocarcinoma. *Oncotarget*. 2017;8(32):52913-22.
50. Liu J, Wan L, Lu K, Sun M, Pan X, Zhang P, et al. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma. *PloS one*. 2015;10(5):e0114586.
51. Lv D, Bi Q, Li Y, Deng J, Wu N, Hao S, Zhao M. Long non-coding RNA MEG3 inhibits cell migration and invasion of non-small cell lung cancer cells by regulating the miR-21-5p/PTEN axis. *Molecular medicine reports*. 2021;23(3).
52. Zhou Y, Sheng B, Xia Q, Guan X, Zhang Y. Association of long non-coding RNA H19 and microRNA-21 expression with the biological features and prognosis of non-small cell lung cancer. *Cancer gene therapy*. 2017;24(8):317-24.
53. Zhao Y, Wang W, Guan C, Hu Z, Liu L, Li W, Jiang X. Long noncoding RNA HOTAIRM1 in human cancers. *Clinica chimica acta; international journal of clinical chemistry*. 2020;511:255-9.
54. Gu D, Tong M, Wang J, Zhang B, Liu J, Song G, Zhu B. Overexpression of the lncRNA HOTAIRM1 promotes lenvatinib resistance by downregulating miR-34a and activating autophagy in hepatocellular carcinoma. *Discover Oncology*. 2023;14(1):66.
55. Feng C, Zhao Y, Li Y, Zhang T, Ma Y, Liu Y. LncRNA MALAT1 Promotes Lung Cancer Proliferation and Gefitinib Resistance by Acting as a miR-200a Sponge. *Archivos de bronconeumologia*. 2019;55(12):627-33.
56. Song J, Su ZZ, Shen QM. Long non-coding RNA MALAT1 regulates proliferation, apoptosis, migration and invasion via miR-374b-5p/SRSF7 axis in non-small cell lung cancer. *European review for medical and pharmacological sciences*. 2020;24(4):1853-62.
57. Xu Y, Liu H, Xiong W, Peng Y, Li X, Long X, et al. A novel mechanism regulating pyroptosis-induced fibrosis in endometriosis via lnc-MALAT1/miR-141-3p/NLRP3 pathway. *Biology of reproduction*. 2023.
58. Esposito R, Polidori T, Meise DF, Pulido-Quetglas C, Chouvardas P, Forster S, et al. Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities. *Cell genomics*. 2022;2(9):100171.

59. Chen YR, Wu YS, Wang WS, Zhang JS, Wu QG. Upregulation of lncRNA DANCR functions as an oncogenic role in non-small lung cancer by regulating miR-214-5p/CIZ1 axis. *European review for medical and pharmacological sciences*. 2020;24(5):2539-47.
60. He F, Song Z, Chen H, Chen Z, Yang P, Li W, et al. Long noncoding RNA PVT1-214 promotes proliferation and invasion of colorectal cancer by stabilizing Lin28 and interacting with miR-128. *Oncogene*. 2019;38(2):164-79.
61. Qi G, Li L. Long non-coding RNA PVT1 contributes to cell growth and metastasis in non-small-cell lung cancer by regulating miR-361-3p/SOX9 axis and activating Wnt/ β -catenin signaling pathway. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2020;126:110100.
62. Wei CM, Zhao XF, Qiu HB, Ming Z, Liu K, Yan J. The long non-coding RNA PVT1/miR-145-5p/ITGB8 axis regulates cell proliferation, apoptosis, migration and invasion in non-small cell lung cancer cells. *Neoplasma*. 2020;67(4):802-12.
63. Xi Y, Shen W, Jin C, Wang L, Yu B. PVT1 Promotes the Proliferation and Migration of Non-Small Cell Lung Cancer via Regulating miR-148/RAB34 Signal Axis. *OncoTargets and therapy*. 2020;13:1819-32.
64. Győrffy B. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. *GeroScience*. 2023.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.